Quince Therapeutics (QNCX) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 11, 2026, and will be held virtually, allowing shareholders to vote and ask questions online.

• Shareholders of record as of April 23, 2026, are eligible to vote on key proposals, including director election, a reverse stock split, auditor ratification, executive compensation, and potential adjournment.

• The board recommends voting in favor of all proposals and has provided detailed proxy materials online for shareholder review.

Voting matters and shareholder proposals

• Proposals include electing June Bray as Class I director, approving a reverse stock split (1-for-10 to 1-for-100), ratifying BDO USA, P.C. as auditor, an advisory vote on executive compensation, and potential adjournment.

• The board recommends voting FOR all proposals.

• Shareholders may submit proposals for the 2027 meeting by December 31, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• The board is classified into three classes with staggered three-year terms to ensure continuity and stability.

• Board leadership is separated, with an independent chairperson and no lead independent director currently.

• All non-management directors are independent per Nasdaq and SEC rules; committees include audit, compensation, and nominating/governance.

• The board values diversity and actively seeks candidates with varied backgrounds and expertise.

• Directors are encouraged to attend annual meetings, and a code of conduct and insider trading policy are in place.